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Abstract
The LRRK2 gene is a major contributor to genetic risk for Parkinson’s disease and understanding the biology of the leucine-rich
repeat kinase 2 (LRRK2, the protein product of this gene) is an important goal in Parkinson’s research. LRRK2 is a multi-domain,
multi-activity enzyme and has been implicated in a wide range of signalling events within the cell. Because of the complexities of
the signal transduction pathways in which LRRK2 is involved, it has been challenging to generate a clear idea as to how
mutations and disease associated variants in this gene are altered in disease. Understanding the events in which LRRK2 is
involved at a systems level is therefore critical to fully understand the biology and pathobiology of this protein and is the subject
of this review.
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Introduction
Leucine-rich repeat kinase 2 (LRRK2) is a large (268-kDa)
multi-domain protein member of the Roco protein family
(Civiero et al. 2014). It is characterised by a complex domain
architecture, including two enzyme domains: a ROCO
GTPase supradomain incorporating Ras of complex proteins
(ROC) and C-terminal of ROC (COR) domains; and a serine/
threonine kinase domain. It has been proposed that the kinase
activity of LRRK2 is intimately linked to that of the ROC
domain. At the N-terminus, protein interaction domains are
present including Armadillo, Ankyrin, and leucine-rich repeat
domains, whereas the C-terminus includes a WD40 domain.
The domain organisation of LRRK2 strongly implicates this
protein in the command and control of signal transduction
within the cell—borne out by experimental investigations into
LRRK2 function, with LRRK2 linked to the regulation of a
range of pathways and signal transduction cascades. Many of
these are vital for homeostasis, including mechanisms such as
proliferation, apoptosis, inflammation, cytokine activation,
synaptogenesis and maintenance and autophagy (Wallings
et al. 2015).
LRRK2 in disease
LRRK2 first came to prominence due to the association of the
LRRK2 gene with Parkinson’s disease (PD). In 2002,
Funayama et al. described a locus on chromosome 12 linked
to PD in a family from the Sagamihara region of Japan
(Funayama et al. 2002), and, in 2004, two independent groups
identified autosomal dominant mutations in the LRRK2 gene
(Paisán-Ruíz et al. 2004; Zimprich et al. 2004). Subsequent
studies have revealed that LRRK2 is a central player in the
genetics of PD, with coding variants being the most common
genetic cause of familial disease and more subtle common
variation at the LRRK2 locus linked to genome-wide associ-
ated risk (Ross et al. 2011; Trabzuni et al. 2013). One aspect of
LRRK2 PD that is in contrast with the idiopathic form of
disease is the pathology observed in cases with mutations.
Whilst the majority of LRRK2 cases present with the Lewy
body pathology associated with classical PD (Hughes et al.
1992), a significant minority present with neurofibrillary
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tangle pathology similar to that observed in progressive
supranuclear palsy or TDP-43 pathology (Wider et al. 2010).
A large number of coding changes in the LRRK2 gene have
been identified but only six have strong evidence for patho-
genicity in PD (Ross et al. 2011): R1441C/G, N1437H,
Y1699C, G2019S and I2020T (Kalia et al. 2015;
Puschmann et al. 2012; Greene et al. 2014). In addition to
these highly penetrant causative factors, coding variants in
LRRK2 with increased risk for PD have been identified, such
as M1646 T and G2385R, as well as a potentially protective
haplotype N551 K-R1398H-K1423 K (Ross et al. 2011)
(Fig. 1).
Of the coding variants strongly associated with disease,
G2019S is the most prevalent and varies by ethnic back-
ground: from 0.1% in Asians and 13% in Ashkenazi Jews to
41% in North African populations (Chien et al. 2014; Li et al.
2014). Interestingly, mutation carriers can be symptom free
beyond their 8th decade (Sierra et al. 2011; Trinh et al.
2014). This demonstrates that these mutations show age-
dependent but incomplete penetrance. The overall penetrance
of G2019S can vary between populations, with a later age of
onset and lower penetrance in Norwegian carriers of the
G2019S variant compared to other populations (Trinh et al.
2014).
The precise molecular consequences of mutations in
LRRK2 are not yet completely clear; however, a common
theme is alterations in enzymatic activity. The causative mu-
tations described above all localise to the enzymatic core of
LRRK2, spanning the GTPase to Kinase domain and the ma-
jority of these coding variants alter LRRK2 enzymatic func-
tion. The G2019S mutation has been robustly associated with
an increase in kinase activity (Greggio and Cookson 2009),
with mutations in the ROC/COR domains (e.g., R1441C,
Y1699C) demonstrating reduced GTPase activity (Lewis
et al. 2007; Daniẽls et al. 2011). These data, repeatedly
highlighting the enzymatic functions of LRRK2 and their role
in the control of signalling pathways, strongly suggest that
perturbations in signal transduction lie at the heart of
LRRK2 dysfunction in PD.
Intriguingly, variation at the LRRK2 locus has also been
connected by genome-wide association with immune diseases
such as systemic lupus erythematosus (Zhang et al. 2017),
Crohn’s disease (Barrett et al. 2008) and inflammatory bowel
disease (Liu et al. 2011) and with susceptibility to
multibacillary leprosy (Wang et al. 2015; Fava et al. 2016).
LRRK2 has also been linked to cancer, with the PD G2019S
mutation associated with specific cancers such as non-skin
and hormonal cancers (Agalliu et al. 2015) and the R1441C
mutation linked to increased risk of colon cancer (Tacik et al.
2016).
Deciphering what LRRK2 does has, therefore, important
ramifications for efforts to target a wide range of human dis-
eases. To achieve this, a key challenge is to develop a detailed
understanding of LRRK2’s function as a signalling molecule
within the cell, an area of biology that has received an excep-
tional amount of attention over the past decade.
LRRK2 as a signalling molecule
As noted above, the specific domains and structure of LRRK2
implicate it in the regulation of cellular signal transduction
events, the dissection of which will be critical for understand-
ing LRRK2s cellular function and the role that it plays in
disease. This task is somewhat complicated by the extensive
Fig. 1 Disease-associated coding
variants in LRRK2. Penetrant
mutations associated with
Parkinson’s disease are displayed
in red, protective variants in green
and disease-associated risk vari-
ants in blue
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list of putative protein binding partners and cellular processes
to which LRRK2 has been linked (Manzoni et al. 2015).
Determining which of these processes and interactors are
physiologically relevant and beyond that relevant to disease,
is a significant challenge.
The array of pathways and interactors with which LRRK2
has been linked is at least partly due to the intrinsic scaffolding
properties of this protein. Outside of its enzymatic activities,
LRRK2 possesses a number of protein/protein interaction mo-
tifs. The N-terminus harbours Ankyrin, Armadillo and
leucine-rich repeats. Ankyrin repeats are found in molecules
with cell–cell signalling functions and typically facilitate pro-
tein interactions or assist in protein recognition (Mosavi et al.
2004). Armadillo repeats have been described in structural
roles and vesicle dynamics (Striegl et al. 2010). Leucine-rich
repeats are often found within proteins with conserved func-
tions in innate immunity involving pathogen recognition (Ng
and Xavier 2011). In addition to these domains, a C-terminal
WD40 domain is present. This class of domain has been im-
plicated in several functions including protein scaffolding and
interactions (Stirnimann et al. 2010). This could indicate re-
peat regions mediating and supporting kinase function; or a
possible role for LRRK2 as a signalling molecule independent
of the kinase (Guaitoli et al. 2016).
An added layer of complexity is provided by data demon-
strating that LRRK2 can form homodimers, with kinase func-
tion reported to be dependant upon this phenomenon (Greggio
et al. 2008; Berger et al. 2010). The reciprocal nature of this
relationship is evidenced by studies suggesting that disruption
of GTPase and kinase activities can act to prevent dimeriza-
tion, thereby reducing kinase activity. It is of note that some
pathogenic mutations cause a shift in dimer formation, pro-
ducing more dimers compared to single proteins, consequent-
ly increasing kinase function whilst decreasing GTPase activ-
ity. This demonstrates the complex relationship between
LRRK2 structure, dimerization and function, possibly allud-
ing to an intramolecular mechanism to regulate domain func-
tion (Sen et al. 2009). In this regard, the absence of an atomic
resolution structure for LRRK2 is a major hindrance to de-
tailed mechanistic insight, although this has been partly miti-
gated by the development of a model for the LRRK2
holoprotein based upon cryo-electron microscopy density
mapping (Guaitoli et al. 2016) .
Importantly, the potential link between LRRK2 kinase ac-
tivity and cellular function, coupled to dysfunction of LRRK2
in disease, specifically the observation of increased kinase
activity by some mutations, has spurred the development of
small molecule inhibitors targeting this enzymatic activity
(Atashrazm and Dzamko 2016). In addition to their potential
therapeutic value, these have proven to be powerful tools for
investigating the signalling events surrounding LRRK2, for
example aiding in the identification and validation of
LRRK2 kinase substrates (Steger et al. 2016).
The pathways and signalling events linked to LRRK2 can
be broadly divided into those that have evidence of a direct
interaction with LRRK2, either through protein/protein inter-
actions or enzymatic activities and those that occur at a dis-
tance through multiple intermediaries. Characterising these
events in a systematic fashion, and developing a physiologi-
cally relevant model for the LRRK2 signalling system, has the
potential to be of great use in advancing our understanding of
LRRK2’s cellular role.
Proximal signalling events
A wide range of direct interactions with LRRK2 have been
reported in the literature. These relate to phosphorylation
events (both of and by LRRK2) and to direct protein/protein
interactions.
Regulation of LRRK2
As is to be expected of a protein implicated in a range of
critical physiological processes, the regulation of LRRK2 de-
scribed to date is complex, with a number of posttranslational
modifications and protein interactions governing the activity
of the LRRK2 protein complex. In common with many en-
zymes involved in signal transduction, phosphorylation ap-
pears to play an important role in governing LRRK2 enzymat-
ic activity and function (Fig. 2). Several groups have deter-
mined phosphorylation sites on LRRK2 that act to regulate
function and downstream signalling events. There is experi-
mental evidence for phosphorylation at S860, S910, S935,
S955 and S973 (Doggett et al. 2012); however, not all of these
potential sites have been associated with specific kinases or
characterised in detail. The precise identity of the kinases in-
volved in these phosphorylation events remains an area of
some debate, although there is evidence that the IkappaB ki-
nase family, including tank binding kinase 1 (TBK1), is re-
sponsible for a proportion of the phosphorylation found on
these residues (Dzamko et al. 2012). Casein kinase I has also
been nominated as an upstream regulator of LRRK2 (Chia
et al. 2014). LRRK2 has also been shown to undergo auto-
phosphorylation at S1292 (Sheng et al. 2012), T2031, S2032
and T2035 (Li et al. 2010). Phosphorylation at S1292 has an
particularly interesting consequence, as this has been shown to
regulate the activity of the GTPase domain thereby potentially
altering signal transduction, translation and other vital cellular
processes (Liu et al. 2016). Protein phosphatase 1 has also
been identified as being able to regulate LRRK2 by dephos-
phorylation (Lobbestael et al. 2013), potentially indicating
that further phosphatases could interact in this way.
The phosphorylation of LRRK2 in this region and in par-
ticular at S910 and S935, is intimately linked with the ability
of LRRK2 to interact with 14–3-3 proteins (Nichols et al.
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2010; Li et al. 2011; Doggett et al. 2012). This interaction, in
turn, has a key role in cellular localisation of LRRK2 with
likely consequences for physiological function. This example
clearly demonstrates the deep-seated connection between
phospho-regulation, protein/protein interactions and protein
function that is central to the control signal transduction by
LRRK2—with reciprocal relationships controlling where
LRRK2 is located within the cell, how active are its enzymatic
activities and with what partners it interacts. Beyond phospho-
regulation, LRRK2 activity may be influenced by other post-
translational modifications such as acetylation and glycosyla-
tion. There is certainly evidence for regulation of LRRK2
prior to translation via the production of splice isoforms
(Trabzuni et al. 2013). These have not yet been subjected to
the same level of scrutiny as phosphor-regulation and repre-
sent a significant gap in our understanding of LRRK2 biology.
Regulation of other proteins by LRRK2
As displayed in Table 1, a number of proteins have been
reported to be directly regulated by LRRK2, predominantly
by phosphorylation. The proportion of these that have been
carefully validated, subject to replication by multiple groups
and using multiple independent techniques, is, however, much
smaller. Examples of direct kinase substrates reported for
LRRK2 include a number of members of the mitogen-
activated protein kinase family, the microtubule-associated
protein Tau, the eukaryotic translation initiation factor 4E–
BP1 and several members of the Rab GTPase family. 4E–
BP1 provides an interesting case study in the challenges pre-
sented by verifying phosphorylation events. This was origi-
nally reported as a substrate for LRRK2 in 2008 based upon
data in a Drosophila melanogaster model for LRRK2 dys-
function (Imai et al. 2008), a study that included in vitro data
suggesting that human LRRK2 could directly phosphorylate
4E–BP1. Subsequent studies from a number of groups have
failed to conclusively demonstrate that 4E–BP1 acts as a di-
rect substrate for LRRK2, or that 4E–BP1 is dysregulated
when LRRK2 activity is altered (Kumar et al. 2010;
Trancikova et al. 2012; Manzoni et al. 2013a, b), although
there are conflicting data on this (Pons et al. 2012). This ex-
ample highlights the complexities of validating phosphoryla-
tion events, events that can be both transitory and highly con-
text dependent in nature.
More recently, a consortium of researchers reported Rab-8
and Rab-10 as phospho-substrates for LRRK2, a study that
again provides a valuable example of the challenges in iden-
tifying bona fide interactors (Steger et al. 2016). The Rab
proteins were identified using a combinatorial proteomic ap-
proach, carrying out an unbiased screen of altered phosphor-
ylation in labelled cells following inhibition of LRRK2 kinase
activity with a panel of specific inhibitors. These were then
validated using a combination of in vitro and cellular ap-
proaches, including the generation of phospho-specific anti-
bodies and artificial mutations. These represent probably the
most thoroughly validated substrates for LRRK2 to date (oth-
er than LRRK2 itself) and yet—as will be discussed further
below—despite this the impact of mutations on phosphoryla-
tion of these substrates is not yet completely clear. More recent
data have highlighted a range of Rab proteins as being poten-
tially phosphorylated by LRRK2, including Rab-3 A/B/C/D,
Rab-12, Rab-35 and Rab-43, in addition to Rab-8 and Rab-10
(Steger et al. 2017). Of these, phosphoregulation of Rab-10
and Rab-12 has recently been replicated by an independent
group (Thirstrup et al. 2017).
Distal signalling events
The proximal, immediate signalling events described above
have significant consequences downstream in a range of
Fig. 2 Phospho-events regulating
LRRK2. Autophosphorylation is
shown in purple, phosphorylation
events mediated by another
kinase in blue
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Table 1 Annotated LRRK2 substrates from protein/protein interaction databases
Name No. of publications Direction of interaction
AKT1 PKB RAC 1 A phosphorylates B
ARFGAPI ARF1GAP 2 A phosphorylates B
ARHGEF7 COOL1 KIAA0142 P85SPR PAK3BP
PIXB Nbla10314
3 A phosphorylates B
CSNK1A1 1 B phosphorylates A
DNM1L DLP1 DRP1 1 A phosphorylates B
EEF1A2 EEF1AL STN 1 Co-incubation of recombinant LRRK2 and EFTA significantly reduces
the kinase activity of LRRK2. Co-incubation of EF1Awith LRRK2
impaired tubulin polymerisation by EFTA
ElF4EBP1 2 A phosphorylates B
GSK3B 1 LRRK2 directly associates with GSK-36 and this interaction
enhances the kinase activity of GSK-3β
HSPD1 HSP60 1 hsp60 may perform a chaperone action in maintaining the proper
folding of recombinant LRRK2 kinase domain in Escherichia coll.
LDHB 1 A phosphorylates B
MAP1B 2 A phosphorylates B
MAP2K3 MEK3 MKK3 PRKMK3 SKK2 2 A phosphorylates B
MAP2K4 JNKK1 MEK4 MKK4 PRKMK4 SEK1
SERK1 SKK1
1 A phosphorylates B
MAP2K6 MEK6 MKK6 PRKMK6 SKK3 2 A phosphorylates B
MAP2K7 JNKK2 MEK7 MKK7 PRKMK7 SKK4 2 A phosphorylates B
MAPT MAPTL MTBT1 TAU 2 A phosphorylates B
MBP 6 A phosphorylates B
MSN 10 A phosphorylates B
PRDX3 AOP1 1 A phosphorylates B
PRKACA PKACA 1 B phosphorylates A
PRKCZ PKC2 1 B phosphorylates A
RAB10 1 A phosphorylates B
RABIA RAB1 1 A phosphorylates B
RAB1B 1 A phosphorylates B
RAB5B 2 A phosphorylates B
RAB8A MEL RAB8 1 A phosphorylates B
RGS2 GOS8 GIG31 1 Recombinant RGS2 inhibited kinase activity of full-length
LRRK2 in vitro in a dose-dependent manner
RIPK2 CARDIAK RICK RIP2 UNQ277/PRO314/
PRO34092
1 A phosphorylates B
RPL10A NEDD6 1 A phosphorylates B
RPL13 BBC1 OK/SW-c1.46 1 A phosphorylates B
RPL14 1 A phosphorylates B
RPL17 1 A phosphorylates B
RPL21 1 A phosphorylates B
RPL23A 1 A phosphorylates B
RPL30 1 A phosphorylates B
RPL34 1 A phosphorylates B
RPL36A RPL44 GIG15 MIG6 1 A phosphorylates B
RPL39 1 A phosphorylates B
RPS11 1 A phosphorylates B
RPS13 1 A phosphorylates B
RPS15 RIG 2 A phosphorylates B
RPS16 1 A phosphorylates B
RPS18 D6S218E 1 A phosphorylates B
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signalling networks and physiological processes. I LRRK2
signalling has been shown in influence autophagy, mitochon-
drial function, transcription, molecular structural integrity and
parts of the immune response. A detailed discussion of the
pathways potentially regulated by LRRK2 is beyond the
scope of this review; however, there are several excellent re-
cent articles that cover this is area in depth (Wallings et al.
2015; Roosen and Cookson 2016; Kang and Marto 2017).
In 2006, it was found that LRRK2 likely localises to vesic-
ular and membranous structures within neurons—leading to
the suggestion that the protein is involved in regulation of
vesicular structures within the brain (Biskup et al. 2006).
This suggestion has been further investigated by numerous
groups and has expanded to encompass synaptic vesicle traf-
ficking (Cirnaru et al. 2014), endosomal and trans-Golgi
sorting (MacLeod et al. 2013; Beilina et al. 2014) and autoph-
agy (Plowey et al. 2008; Alegre-Abarrategui et al. 2009). Of
these, autophagy is one of the most intensively studied; how-
ever, many aspects of this are still not fully understood. A
number of these studies have focused on the expression of
G2019S LRRK2 and indicate that this mutation promotes an
increase of autophagic vacuoles and other autophagic abnor-
malities in both SH-SY5Y cells (Plowey et al. 2008) and
transgenic mice (Ramonet et al. 2011).
Several studies have suggested that mitochondrial dysfunc-
tion could be mediated by LRRK2 in some way. Some PD-
associated mutations, such as G2019S, exacerbate the wild-
type LRRK2 function of mitochondrial fragmentation causing
release of cytotoxic and damaging substances (Wang et al.
2012). These damaged organelles would be subject to
degradation by autophagy (specifically via mitophagy, a
specialised form of autophagy)—another function that has
been shown to be influenced by LRRK2.
Another process that has been linked to LRRK2 is tran-
scriptional regulation, as reviewed in detail by Berwick and
Harvey (2011). Further to this, groups have altered LRRK2
expression to identify specific functions and molecules
impacted by a modulation of transcription. Nikonova et al.
(2012) compared gene expression in transgenic LRRK2
wild-type, knockout and G2019S mutated mice. It was found
that transcription activity was upregulated in G2019S mice
compared to knockout and wild-type when each LRRK2 con-
dition was overexpressed. This suggests that LRRK2 has
some function or influence on the transcription process
(Nikonova et al. 2012), although again the data on this are
conflicting (Devine et al. 2011).
It has been shown that LRRK2 is abundantly expressed in
immune cells and enhances NF-κB-dependent transcription,
thereby suggesting a role within immune signalling. A num-
ber of studies have revealed a deficiency or alteration in the
immune response upon knockdown of LRRK2 (Kim et al.
2012; Wandu et al. 2015) and, additionally, LRRK2 has been
shown to be a potential substrate for proteins such as the
cytokine IFN-γ (Gardet et al. 2010) and the IKK family of
kinases, including TBK1 (Dzamko et al. 2012). Whilst this
does not conclusively associate LRRK2 with immune func-
tion at a molecular level, there is clearly a potential influence
that merits further investigation, especially given genetic evi-
dence linking LRRK2 to disorders with a strong immune
component.
Table 1 (continued)
Name No. of publications Direction of interaction
RPS2 RPS4 1 A phosphorylates B
RPS23 1 A phosphorylates B
RPS27 MPS1 1 A phosphorylates B
RPS3 OK/SW-c1.26 1 A phosphorylates B
SH3GL1 CNSA1 SH3D2B 1 A phosphorylates B
SH3GL2 CNSA2 SH3D2A 2 A phosphorylates B
SH3GL3 CNSA3 SH3D2C 1 A phosphorylates B
SNAPIN BLOC1S7 SNAP25BP SNAPAP 1 A phosphorylates B
STK24 MST3 STK3 1 A phosphorylates B
STK25 SOK1 YSK1 1 A phosphorylates B
STK3 KRS1 MST2 1 A phosphorylates B
TAOK3 DPK JIK KDS MAP3K18 1 A phosphorylates B
TP53 P53 1 A phosphorylates B
TUBA1ATUBA3 1 A phosphorylates B
LRRK2 PARKS 26 A phosphorylates A
The terms: APID, Interactomes, BioGrid, bhf-ucl, InnateDB, InnateDB-All, IntAct, mentha, MINT, InnateDB-IMEx, UniProt and MBInfo were
searched for LRRK2 interactions and those described as phosphorylation events were extracted. The direction of phosphorylation was determined by
manually curating each entry and referring back to the original study. A fully referenced version of this table is available as supplemental Table 1
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Mutations in the context of the LRRK2 signalling
system
As noted above, one of the key drivers of research into
LRRK2 is the important role that this protein plays in the
etiogenesis of PD. Given the clear impact of mutations in
LRRK2 enzymatic activities of this protein, it follows that
these mutations will have a significant impact on the signal-
ling events regulated by LRRK2. Discerning a clear pattern in
precisely how, and in what direction, mutations perturb
LRRK2-dependent signalling has, however, proved a signifi-
cant challenge. Based on data from purified recombinant pro-
tein, there is not a clear consistent impact of LRRK2 muta-
tions on intrinsic kinase or GTPase activity. The G2019S var-
iant results in heightened kinase activity as measured by a
wide range of putative substrates but this is not matched
in vitro by other disease-associated variants (Greggio and
Cookson 2009). There is a consistent decrease in intrinsic
GTP hydrolysis in the presence of mutations in the ROC
and COR domains (e.g., the R1441C and Y1699Cmutations);
however, this activity has not been exhaustively examined for
disease-associated variants in the kinase domain such as
G2019S and there is some evidence that GTP hydrolysis is
increased by the I2020T variant (Lewis et al. 2007; Xiong
et al. 2010; Daniẽls et al. 2011; Tsika and Moore 2013; Ho
et al. 2016).
To further confuse matters, when downstream phosphory-
lation events are examined in cellular systems, disease-
associated variants appear to do different things depending
on the specific event. This can be illustrated by examining
three examples: phosphorylation of LRRK2 on S910/S935
(phosphorylation events that are not due to autophosphoryla-
tion but display some dependency on LRRK2 kinase activity),
phosphorylation at S1292 (thought to be autophosphoryla-
tion) and phosphorylation of Rab-8 and Rab-10. In the case
of the former, phosphorylation at S910 and S935 is signifi-
cantly decreased by the R1441G, Y1699C and I2020T muta-
tions but not altered by the R1441C and G2019S mutations
(Nichols et al. 2010; Li et al. 2011). Notably, kinase-dead
forms of LRRK2 do not altered S910/S935 phos-
phorylation, although acute inhibition of kinase activity does
decrease phosphorylation at these residues (Dzamko et al.
2010). Phosphorylation at S1292 is increased by PD-
associated mutations in LRRK2, with the exception of
Y1699C, and is dependent upon LRRK2 kinase and GTPase
activi ty (Sheng et al . 2012; Steger et al . 2016).
Phosphorylation of Rab-8 and Rab-10 at T72 and T73, respec-
tively, is increased by mutations in LRRK2, other than the
G2019S variant, when examined in cells (Steger et al. 2016).
Examined in vitro, however, the G2019S increases phosphor-
ylation of Rab-8 at T72 and the R1441C variant is indistin-
guishable from wild-type, the opposite of what is observed in
cells. These data are summarised in Table 2. It is also
noteworthy that the mutation of S910 and S935 to alanine
residues does not alter phosphorylation of S1292 (thought to
be an autophosporylation event) but does alter phosphoryla-
tion of Rab-10 (Ito et al. 2016).
A reasonable interpretation of the available data is that the
in vitro data do not fully recapitulate the activity of LRRK2 in
intact systems. It is likely that LRRK2-dependent phosphory-
lation events are influenced by GTP–GDP turnover in cells,
which might in turn be related to membrane association and/or
dimerization of LRRK2. Localisation and allosteric changes
in the structure of the LRRK2 complex, as well as the pres-
ence or absence of co-factors (protein or otherwise), could
also underly the discrepancies between in vitro and
ex vivo/in vivo data. Disentangling these possibilities presents
a major challenge to the field but will be important for resolv-
ing some of the inconsistencies in the literature between data
from recombinant protein and those in cells.
Modelling the LRRK2 signalling system
Delineating the consequences of mutations in LRRK2 and the
impact of manipulating this enzyme through the use of small-
molecule inhibitors relies on a high-resolution map of the sig-
nalling events surrounding this protein. Although many of the
details of LRRK2-dependent signalling remain to be clarified,
significant progress has been made in recent years both at a
structural and a cellular level (Guaitoli et al. 2016; Steger et al.
2016). Bringing these data together into a comprehensive tem-
plate for LRRK2 signalling has many potential benefits for re-
search into LRRK2. First, it can provide a framework for devel-
oping and testing hypotheses centred around LRRK2 function
in signalling networks. This approach has proved extremely
valuable in analysing other complex signalling events, for ex-
ample the regulation and activity of the mammalian/mechanistic
target of the rapamycin (mTOR) kinase complex (Caron et al.
2010). It should be noted, however, that the level of system
resolution for mTOR signalling—including detailed, verified
interaction mapping and Ångström resolution structures—is
much higher than our current comprehension of LRRK2 signal-
ling (Kang et al. 2013; Aylett et al. 2016). The power provided
by systems level network models is exemplified by the applica-
tion of this to macroautophagy downstream ofmTOR (pertinent
to studies of LRRK2 given the reported links between LRRK2
and autophagy), allowing an integrated overview of what is an
extremely complex and dynamic process (Kramer et al. 2017).
At an individual signalling event level, developing a system
map for LRRK2 opens the possibility of constructing mathe-
matical models for regulation of and by LRRK2 based upon
detailed time course datasets for LRRK2-mediated signalling
events. Again, similar approaches applied to other signal trans-
duction pathways have proved very valuable, for example yield-
ing insights into GPVI signalling (Dunster et al. 2015). An
example of how a systems approach could be applied to
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LRRK2 regulation is provided in Fig. 3, focusing on a group of
signalling events that have been characterised in detail:
phosphoregulation of S910 and S935, 14–3-3 binding and phos-
phorylation of Rab 8 and 10. The network is annotated using an
established rubric for bioregulatory networks (Kohn et al. 2005).
These individual events are suitable for detailed mechanistic
investigation, generating datasets that can be used to elucidate
kinetic parameters, which, in turn, can be used to generate math-
ematical models describing these events. Once integrated, these
can then be used to generate predictions as to how the system
will react to perturbation with, for example, LRRK2 kinase
inhibitors, or by mutations with known (and quantified) impacts
on kinase/GTPase activity. Any observed differences between
these predictions and experimentally generated data from cellu-
lar models can then be fed into an iterative process whereby
mathematical models for LRRK2 function can be modified to
mirror experimental data.
Conclusions
LRRK2 has been implicated in many functions, both directly
through protein interaction and phosphorylation and indirectly
through signal transduction cascades. Gaining a deeper under-
standing of these pathways is critical for comprehending
LRRK2s physiological function as well as its role in the multi-
tude of diseases towhich it has been linked. As outlined, thinking
about LRRK2 as part of a signalling system provides a poten-
tially valuable tool to tackle this challenge. This will be of par-
ticular importance as LRRK2 inhibitors edge closer to clinical
trials, especially as there is clear evidence of on-target alterations
in key organs including the lung (Fuji et al. 2015). In particular,
the potential for downstream LRRK2-specific phosphorylation
events to act as biomarkers for disease or for evidence of target
engagement may have a critical role in assessing LRRK2 kinase
inhibitors in first-in-human trials (Fan et al. 2017; Lis et al. 2017).
Fig. 3 An example of a simplified
regulatory network for LRRK2
signalling biology, showing
phosphorylation events and
protein/protein interactions
Table 2 Impact of mutations and inhibition on phosphorylation events associated with LRRK2. Increased phosphorylation is indicated in green,
decreased phosophorylation in red, no significant chagne in yellow and no date in white
Mutations: R1441C (RC), R1441G (RG), R1441H (RH), Y1699C (YC), G2019S (GS), I2020T (IT), Kinase dead (KD), inhibitor treatment (IN). Data
from indicated references: * Nichols et al. 2010, Dzamko et al. 2010 # Li et al. 2011 ¶ Sheng et al. 2012 § Steger et al. 2016
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Looking beyond disease, the multi-activity nature of the LRRK2
protein complex has the potential to yield important insights into
the fundamental rules governing signal transduction, ensuring
that this fascinating protein will remain the subject of detailed
investigation for the foreseeable future.
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